{"slug":"tnbc-deep-dive","tag":"tnbc-deep-dive","variants":["tnbc-deep-dive"],"description":"Registry-only phase 2 and 3 trials that name triple-negative breast cancer in their title or conditions, recorded from ClinicalTrials.gov during the triple-negative breast cancer deep dive.","count":213,"kinds":{"trial":213},"related":[],"records":[{"id":"nct02641847","kind":"trial","name":"TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature","route":"/trials/nct02641847/","status":"active","tldr":"A phase 2/3 trial of docetaxel, doxorubicin, epirubicin, cyclophosphamide and other drugs in triple-negative breast cancer, run by Fudan University, active but no longer recruiting."},{"id":"nct01057069","kind":"trial","name":"Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer","route":"/trials/nct01057069/","status":"active","tldr":"A phase 2/3 trial of carboplatin, paclitaxel / nab-paclitaxel, doxorubicin, cyclophosphamide and other drugs in triple-negative breast cancer, run by The Netherlands Cancer Institute, active but no longer recruiting."},{"id":"nct03168880","kind":"trial","name":"A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced","route":"/trials/nct03168880/","status":"active","tldr":"A phase 3 trial of paclitaxel / nab-paclitaxel and carboplatin in triple-negative breast cancer, run by Tata Memorial Hospital, active but no longer recruiting."},{"id":"nct02488967","kind":"trial","name":"Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer","route":"/trials/nct02488967/","status":"active","tldr":"A phase 3 trial of carboplatin, cyclophosphamide, doxorubicin and paclitaxel / nab-paclitaxel in triple-negative breast cancer, run by NRG Oncology, active but no longer recruiting."},{"id":"nct02455141","kind":"trial","name":"Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer","route":"/trials/nct02455141/","status":"active","tldr":"A phase 3 trial of epirubicin, cyclophosphamide and carboplatin in triple-negative breast cancer, run by Shanghai Jiao Tong University School of Medicine, active but no longer recruiting."},{"id":"nct05552001","kind":"trial","name":"Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer","route":"/trials/nct05552001/","status":"active","tldr":"A phase 3 trial of sacituzumab govitecan in triple-negative breast cancer, run by UNICANCER, active but no longer recruiting."},{"id":"nct04335669","kind":"trial","name":"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC","route":"/trials/nct04335669/","status":"active","tldr":"A phase 3 trial of epirubicin, cyclophosphamide, paclitaxel / nab-paclitaxel, carboplatin and other drugs in triple-negative breast cancer, run by Lund University Hospital, active but no longer recruiting."},{"id":"nct04595565","kind":"trial","name":"Sacituzumab Govitecan in Primary HER2-negative Breast Cancer","route":"/trials/nct04595565/","status":"active","tldr":"A phase 3 trial of capecitabine, carboplatin, cisplatin and sacituzumab govitecan in triple-negative breast cancer, run by GBG Forschungs GmbH, active but no longer recruiting."},{"id":"nct05078047","kind":"trial","name":"Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO","route":"/trials/nct05078047/","status":"active","tldr":"A phase 3 trial in triple-negative breast cancer, run by UNICANCER, active but no longer recruiting."},{"id":"nct04296175","kind":"trial","name":"Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)","route":"/trials/nct04296175/","status":"active","tldr":"A phase 3 trial of epirubicin, paclitaxel / nab-paclitaxel and carboplatin in triple-negative breast cancer, run by Fudan University, active but no longer recruiting."},{"id":"nct06910072","kind":"trial","name":"Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TN","route":"/trials/nct06910072/","status":"recruiting","tldr":"A phase 2/3 trial of carboplatin in triple-negative breast cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting."},{"id":"nct07359404","kind":"trial","name":"Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC","route":"/trials/nct07359404/","status":"recruiting","tldr":"A phase 2 trial of sacituzumab govitecan and bevacizumab in triple-negative breast cancer, run by YING FAN, now recruiting."},{"id":"nct07376629","kind":"trial","name":"A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC","route":"/trials/nct07376629/","status":"recruiting","tldr":"A phase 2 trial of nab-paclitaxel in triple-negative breast cancer, run by Huabo Biopharm Co., Ltd., now recruiting."},{"id":"nct05821686","kind":"trial","name":"Efficacy of Interleukin-2 in Triple Negative Breast Cancer","route":"/trials/nct05821686/","status":"planned","tldr":"A phase 1/2 trial in triple-negative breast cancer, run by Nova Scotia Health Authority, not yet recruiting."},{"id":"nct07107217","kind":"trial","name":"Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer","route":"/trials/nct07107217/","status":"planned","tldr":"A phase 2 trial of camrelizumab, doxorubicin, cyclophosphamide, carboplatin and other drugs in triple-negative breast cancer, run by Blokhin's Russian Cancer Research Center, not yet recruiting."},{"id":"nct06977542","kind":"trial","name":"Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer","route":"/trials/nct06977542/","status":"planned","tldr":"A phase 2 trial of ivonescimab in triple-negative breast cancer, run by Fudan University, not yet recruiting."},{"id":"nct07413601","kind":"trial","name":"Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Secon","route":"/trials/nct07413601/","status":"planned","tldr":"A phase 2 trial of iparomlimab and tuvonralimab, cisplatin and carboplatin in triple-negative breast cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, not yet recruiting."},{"id":"nct07681297","kind":"trial","name":"Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Dis","route":"/trials/nct07681297/","status":"planned","tldr":"A phase 1/2 trial of tislelizumab, bevacizumab and capecitabine in triple-negative breast cancer, run by National University Hospital, Singapore, not yet recruiting."},{"id":"nct04301739","kind":"trial","name":"to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versu","route":"/trials/nct04301739/","status":"planned","tldr":"A phase 3 trial of serplulimab, nab-paclitaxel, carboplatin, doxorubicin and other drugs in triple-negative breast cancer, run by Shanghai Henlius Biotech, not yet recruiting."},{"id":"nct07721259","kind":"trial","name":"A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden","route":"/trials/nct07721259/","status":"planned","tldr":"A phase 2 trial in triple-negative breast cancer, run by University of Washington, not yet recruiting."},{"id":"nct07788222","kind":"trial","name":"Sacituzumab Govitecan and Q901 in Advanced TNBC","route":"/trials/nct07788222/","status":"planned","tldr":"A phase 2 trial of sacituzumab govitecan in triple-negative breast cancer, run by Yonsei University, not yet recruiting."},{"id":"nct07021261","kind":"trial","name":"Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients","route":"/trials/nct07021261/","status":"planned","tldr":"A phase 3 trial of utidelone and capecitabine in triple-negative breast cancer, run by Fudan University, not yet recruiting."},{"id":"nct07743723","kind":"trial","name":"A Study of IOV-5001 in Adults With Advanced Solid Tumors","route":"/trials/nct07743723/","status":"planned","tldr":"A phase 1/2 trial in triple-negative breast cancer, run by Iovance Biotherapeutics, Inc., not yet recruiting."},{"id":"nct07011823","kind":"trial","name":"Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC","route":"/trials/nct07011823/","status":"planned","tldr":"A phase 2 trial in triple-negative breast cancer, run by Gangnam Severance Hospital, not yet recruiting."},{"id":"nct07407517","kind":"trial","name":"Adjuvant Intensification for LAR","route":"/trials/nct07407517/","status":"planned","tldr":"A phase 3 trial in triple-negative breast cancer, run by Fudan University, not yet recruiting."},{"id":"nct07299409","kind":"trial","name":"First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.","route":"/trials/nct07299409/","status":"planned","tldr":"A phase 2 trial of sacituzumab govitecan in triple-negative breast cancer, run by Nathalie Levasseur, not yet recruiting."},{"id":"nct07487519","kind":"trial","name":"Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Br","route":"/trials/nct07487519/","status":"planned","tldr":"A phase 2 trial of serplulimab in triple-negative breast cancer, run by Shanghai Henlius Biotech, not yet recruiting."},{"id":"nct07486687","kind":"trial","name":"Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy","route":"/trials/nct07486687/","status":"planned","tldr":"A phase 3 trial of pembrolizumab and olaparib in triple-negative breast cancer, run by The Netherlands Cancer Institute, not yet recruiting."},{"id":"nct07372079","kind":"trial","name":"Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemoth","route":"/trials/nct07372079/","status":"planned","tldr":"A phase 2 trial in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting."},{"id":"nct06731153","kind":"trial","name":"JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC","route":"/trials/nct06731153/","status":"planned","tldr":"A phase 2 trial of camrelizumab and eribulin in triple-negative breast cancer, run by Fudan University, not yet recruiting."},{"id":"nct07441512","kind":"trial","name":"A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer","route":"/trials/nct07441512/","status":"planned","tldr":"A phase 2 trial of inavolisib and eribulin in triple-negative breast cancer, run by Hu Hai, not yet recruiting."},{"id":"nct07743632","kind":"trial","name":"Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC","route":"/trials/nct07743632/","status":"planned","tldr":"A phase 2 trial of carboplatin, docetaxel, doxorubicin, cyclophosphamide and other drugs in triple-negative breast cancer, run by University of Kansas Medical Center, not yet recruiting."},{"id":"nct07458204","kind":"trial","name":"Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer","route":"/trials/nct07458204/","status":"planned","tldr":"A phase 2 trial in triple-negative breast cancer, run by Institut Jean-Godinot, not yet recruiting."},{"id":"nct05862610","kind":"trial","name":"The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC","route":"/trials/nct05862610/","status":"planned","tldr":"A phase 2 trial of trilaciclib in triple-negative breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, not yet recruiting."},{"id":"nct07752550","kind":"trial","name":"Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer","route":"/trials/nct07752550/","status":"planned","tldr":"A phase 2 trial of retlirafusp alfa, nab-paclitaxel and fluzoparib in triple-negative breast cancer, run by Harbin Medical University, not yet recruiting."},{"id":"nct05522491","kind":"trial","name":"Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer","route":"/trials/nct05522491/","status":"planned","tldr":"A phase 2 trial of olaparib in triple-negative breast cancer, run by Hebei Medical University Fourth Hospital, not yet recruiting."},{"id":"nct06404736","kind":"trial","name":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer","route":"/trials/nct06404736/","status":"planned","tldr":"A phase 2 trial of nab-paclitaxel and carboplatin in triple-negative breast cancer, run by Fudan University, not yet recruiting."},{"id":"nct07509515","kind":"trial","name":"QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.","route":"/trials/nct07509515/","status":"planned","tldr":"A phase 2 trial of iparomlimab and tuvonralimab in triple-negative breast cancer, run by Fudan University, not yet recruiting."},{"id":"nct07015853","kind":"trial","name":"ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation","route":"/trials/nct07015853/","status":"planned","tldr":"A phase 2 trial of pembrolizumab in triple-negative breast cancer, run by Stephen Shiao, not yet recruiting."},{"id":"nct07151586","kind":"trial","name":"Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Lo","route":"/trials/nct07151586/","status":"planned","tldr":"A phase 2 trial of sacituzumab govitecan and trastuzumab deruxtecan in triple-negative breast cancer, run by UNICANCER, not yet recruiting."},{"id":"nct06371807","kind":"trial","name":"Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab","route":"/trials/nct06371807/","status":"planned","tldr":"A phase 2 trial of pembrolizumab in triple-negative breast cancer, run by Fundacao Champalimaud, not yet recruiting."},{"id":"nct07552181","kind":"trial","name":"Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer","route":"/trials/nct07552181/","status":"planned","tldr":"A phase 2 trial in triple-negative breast cancer, run by Yuan Yuan, not yet recruiting."},{"id":"nct07762703","kind":"trial","name":"Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Incl","route":"/trials/nct07762703/","status":"planned","tldr":"A phase 1/2 trial of pembrolizumab and aspirin in triple-negative breast cancer, run by BreakBio Corp, not yet recruiting."},{"id":"nct07292142","kind":"trial","name":"FMT in Triple Negative Breast Cancer Guided by ctDNA","route":"/trials/nct07292142/","status":"planned","tldr":"A phase 1/2 trial in triple-negative breast cancer, run by Jewish General Hospital, not yet recruiting."},{"id":"nct07244874","kind":"trial","name":"Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC","route":"/trials/nct07244874/","status":"planned","tldr":"A phase 2 trial of sacituzumab tirumotecan and toripalimab in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting."},{"id":"nct02802423","kind":"trial","name":"Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.","route":"/trials/nct02802423/","status":"planned","tldr":"A phase 1/2 trial in triple-negative breast cancer, run by BioLite, Inc., not yet recruiting."},{"id":"nct06202313","kind":"trial","name":"Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer","route":"/trials/nct06202313/","status":"planned","tldr":"A phase 2 trial of cadonilimab and eribulin in triple-negative breast cancer, run by Shengjing Hospital, not yet recruiting."},{"id":"nct07040644","kind":"trial","name":"A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC","route":"/trials/nct07040644/","status":"planned","tldr":"A phase 2 trial of sacituzumab govitecan, toripalimab and nab-paclitaxel in triple-negative breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, not yet recruiting."},{"id":"nct06724263","kind":"trial","name":"A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors","route":"/trials/nct06724263/","status":"planned","tldr":"A phase 2 trial in triple-negative breast cancer, run by Tasly Biopharmaceuticals Co., Ltd., not yet recruiting."},{"id":"nct06632405","kind":"trial","name":"A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC","route":"/trials/nct06632405/","status":"planned","tldr":"A phase 2 trial of camrelizumab and nab-paclitaxel in triple-negative breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, not yet recruiting."},{"id":"nct06849492","kind":"trial","name":"HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer","route":"/trials/nct06849492/","status":"planned","tldr":"A phase 2 trial of camrelizumab, nab-paclitaxel, sacituzumab tirumotecan and lenvatinib in triple-negative breast cancer, run by Fudan University, not yet recruiting."},{"id":"nct07054242","kind":"trial","name":"A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Ca","route":"/trials/nct07054242/","status":"planned","tldr":"A phase 2 trial of sacituzumab tirumotecan and pembrolizumab in triple-negative breast cancer, run by Yantai Yuhuangding Hospital, not yet recruiting."},{"id":"nct06746870","kind":"trial","name":"A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Tr","route":"/trials/nct06746870/","status":"planned","tldr":"A phase 2 trial of cisplatin and carboplatin in triple-negative breast cancer, run by ImmuneOnco Biopharmaceuticals (Shanghai) Inc., not yet recruiting."},{"id":"nct05128734","kind":"trial","name":"Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)","route":"/trials/nct05128734/","status":"planned","tldr":"A phase 2 trial of temozolomide and olaparib in triple-negative breast cancer, run by AHS Cancer Control Alberta, not yet recruiting."},{"id":"nct07256964","kind":"trial","name":"Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer","route":"/trials/nct07256964/","status":"planned","tldr":"A phase 2 trial of toripalimab in triple-negative breast cancer, run by Henan Cancer Hospital, not yet recruiting."},{"id":"nct07628504","kind":"trial","name":"Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations","route":"/trials/nct07628504/","status":"planned","tldr":"A phase 3 trial of sacituzumab tirumotecan and capecitabine in triple-negative breast cancer, run by Fudan University, not yet recruiting."},{"id":"nct07101614","kind":"trial","name":"A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy fo","route":"/trials/nct07101614/","status":"planned","tldr":"A phase 2 trial of toripalimab in triple-negative breast cancer, run by Shengjing Hospital, not yet recruiting."},{"id":"nct07103447","kind":"trial","name":"Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC","route":"/trials/nct07103447/","status":"planned","tldr":"A phase 2 trial of ivonescimab and carboplatin in triple-negative breast cancer, run by Shuangyue Liu, not yet recruiting."},{"id":"nct06819319","kind":"trial","name":"SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer","route":"/trials/nct06819319/","status":"planned","tldr":"A phase 2 trial of SHR-A2102 and adebrelimab in triple-negative breast cancer, run by Henan Cancer Hospital, not yet recruiting."},{"id":"nct07161791","kind":"trial","name":"Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer","route":"/trials/nct07161791/","status":"planned","tldr":"A phase 1/2 trial in triple-negative breast cancer, run by Harbin Medical University, not yet recruiting."},{"id":"nct07581314","kind":"trial","name":"Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)","route":"/trials/nct07581314/","status":"planned","tldr":"A phase 1/2 trial in triple-negative breast cancer, run by Telomir Pharmaceuticals, Inc., not yet recruiting."},{"id":"nct06691594","kind":"trial","name":"Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy","route":"/trials/nct06691594/","status":"planned","tldr":"A phase 2 trial in triple-negative breast cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, not yet recruiting."},{"id":"nct07271992","kind":"trial","name":"TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer","route":"/trials/nct07271992/","status":"planned","tldr":"A phase 2 trial of sacituzumab govitecan in triple-negative breast cancer, run by First Hospital of China Medical University, not yet recruiting."},{"id":"nct07153965","kind":"trial","name":"Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer","route":"/trials/nct07153965/","status":"planned","tldr":"A phase 2 trial of sacituzumab tirumotecan in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting."},{"id":"nct07255612","kind":"trial","name":"Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)","route":"/trials/nct07255612/","status":"planned","tldr":"A phase 2 trial of trilaciclib and eribulin in triple-negative breast cancer, run by Sun Yat-sen University, not yet recruiting."},{"id":"nct07730125","kind":"trial","name":"Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies","route":"/trials/nct07730125/","status":"planned","tldr":"A phase 1/2 trial in triple-negative breast cancer, run by CoRegen, Inc., not yet recruiting."},{"id":"nct06140576","kind":"trial","name":"The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breas","route":"/trials/nct06140576/","status":"planned","tldr":"A phase 1/2 trial of nab-paclitaxel and lenvatinib in triple-negative breast cancer, run by Zhejiang Cancer Hospital, not yet recruiting."},{"id":"nct06229067","kind":"trial","name":"Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer","route":"/trials/nct06229067/","status":"planned","tldr":"A phase 2 trial of adebrelimab, vinorelbine, cyclophosphamide and capecitabine in triple-negative breast cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, not yet recruiting."},{"id":"nct06787339","kind":"trial","name":"Capecitabine in Low Risk Triple Negative Breast Cancer","route":"/trials/nct06787339/","status":"planned","tldr":"A phase 2 trial of capecitabine in triple-negative breast cancer, run by Fudan University, not yet recruiting."},{"id":"nct07005583","kind":"trial","name":"Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent","route":"/trials/nct07005583/","status":"planned","tldr":"A phase 2 trial of iparomlimab and tuvonralimab and olaparib in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting."},{"id":"nct07723469","kind":"trial","name":"Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery","route":"/trials/nct07723469/","status":"planned","tldr":"A phase 3 trial in triple-negative breast cancer, run by SURGE Therapeutics, not yet recruiting."},{"id":"nct05067530","kind":"trial","name":"Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a \"Window of Opportunity\" Study","route":"/trials/nct05067530/","status":"planned","tldr":"A phase 2 trial of palbociclib, paclitaxel / nab-paclitaxel and carboplatin in triple-negative breast cancer, run by Medical University of Gdansk, not yet recruiting."},{"id":"nct06795503","kind":"trial","name":"Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients","route":"/trials/nct06795503/","status":"planned","tldr":"A phase 3 trial of docetaxel, cyclophosphamide, epirubicin and paclitaxel / nab-paclitaxel in triple-negative breast cancer, run by Fudan University, not yet recruiting."},{"id":"nct06586866","kind":"trial","name":"JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases","route":"/trials/nct06586866/","status":"planned","tldr":"A phase 2 trial in triple-negative breast cancer, run by JenKem Technology Co., Ltd., not yet recruiting."},{"id":"nct07786428","kind":"trial","name":"Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC","route":"/trials/nct07786428/","status":"planned","tldr":"A phase 2 trial of pembrolizumab, paclitaxel / nab-paclitaxel and carboplatin in triple-negative breast cancer, run by University of Texas Southwestern Medical Center, not yet recruiting."},{"id":"nct07419880","kind":"trial","name":"Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer","route":"/trials/nct07419880/","status":"planned","tldr":"A phase 2 trial of TQB2102 in triple-negative breast cancer, run by Fudan University, not yet recruiting."},{"id":"nct07610525","kind":"trial","name":"Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial","route":"/trials/nct07610525/","status":"planned","tldr":"A phase 2 trial of paclitaxel / nab-paclitaxel, carboplatin and pembrolizumab in triple-negative breast cancer, run by M.D. Anderson Cancer Center, not yet recruiting."},{"id":"nct07729956","kind":"trial","name":"A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inopera","route":"/trials/nct07729956/","status":"planned","tldr":"A phase 3 trial of izalontamab brengitecan and nab-paclitaxel in triple-negative breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., not yet recruiting."},{"id":"nct05806385","kind":"trial","name":"Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers","route":"/trials/nct05806385/","status":"planned","tldr":"A phase 1/2 trial in triple-negative breast cancer, run by Texas Tech University Health Sciences Center, not yet recruiting."},{"id":"nct07528768","kind":"trial","name":"HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry.","route":"/trials/nct07528768/","status":"planned","tldr":"A phase 2 trial of gemcitabine in triple-negative breast cancer, run by The University of The West Indies, not yet recruiting."},{"id":"nct06268327","kind":"trial","name":"Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy","route":"/trials/nct06268327/","status":"planned","tldr":"A phase 2/3 trial of cisplatin, gemcitabine and capecitabine in triple-negative breast cancer, run by Assiut University, not yet recruiting."},{"id":"nct07007780","kind":"trial","name":"Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC","route":"/trials/nct07007780/","status":"planned","tldr":"A phase 2 trial of sacituzumab tirumotecan in triple-negative breast cancer, run by Xijing Hospital, not yet recruiting."},{"id":"nct07139470","kind":"trial","name":"Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer","route":"/trials/nct07139470/","status":"planned","tldr":"A phase 1/2 trial of sacituzumab tirumotecan and anlotinib in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting."},{"id":"nct07458113","kind":"trial","name":"Sac-TMT for Active TNBC Brain Metastases","route":"/trials/nct07458113/","status":"planned","tldr":"A phase 2 trial of sacituzumab tirumotecan in triple-negative breast cancer, run by Yale University, not yet recruiting."},{"id":"nct07556848","kind":"trial","name":"A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct07556848/","status":"planned","tldr":"A phase 3 trial in triple-negative breast cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., not yet recruiting."},{"id":"nct06407310","kind":"trial","name":"Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer","route":"/trials/nct06407310/","status":"planned","tldr":"A phase 2 trial of pembrolizumab, carboplatin and paclitaxel / nab-paclitaxel in triple-negative breast cancer, run by Tel Aviv Medical Center, not yet recruiting."},{"id":"nct07178730","kind":"trial","name":"NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer","route":"/trials/nct07178730/","status":"planned","tldr":"A phase 3 trial of sacituzumab govitecan in triple-negative breast cancer, run by Women's Cancer Study Group GmbH, not yet recruiting."},{"id":"nct07698106","kind":"trial","name":"Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC","route":"/trials/nct07698106/","status":"planned","tldr":"A phase 1/2 trial in triple-negative breast cancer, run by University Health Network, Toronto, not yet recruiting."},{"id":"nct06176261","kind":"trial","name":"DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs","route":"/trials/nct06176261/","status":"recruiting","tldr":"A phase 2 trial of datopotamab deruxtecan in triple-negative breast cancer, run by Nancy Lin, MD, now recruiting."},{"id":"nct04468061","kind":"trial","name":"Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC","route":"/trials/nct04468061/","status":"recruiting","tldr":"A phase 2 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer, run by Dana-Farber Cancer Institute, now recruiting."},{"id":"nct06627712","kind":"trial","name":"SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC","route":"/trials/nct06627712/","status":"recruiting","tldr":"A phase 3 trial in triple-negative breast cancer, run by West China Hospital, now recruiting."},{"id":"nct05447702","kind":"trial","name":"Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)","route":"/trials/nct05447702/","status":"recruiting","tldr":"A phase 2 trial of camrelizumab, rivoceranib (apatinib), nab-paclitaxel, epirubicin and other drugs in triple-negative breast cancer, run by West China Hospital, now recruiting."},{"id":"nct07064018","kind":"trial","name":"Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","route":"/trials/nct07064018/","status":"recruiting","tldr":"A phase 1/2 trial of pegfilgrastim and filgrastim (g-csf) in triple-negative breast cancer, run by University of California, Irvine, now recruiting."},{"id":"nct07378306","kind":"trial","name":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","route":"/trials/nct07378306/","status":"recruiting","tldr":"A phase 2 trial of toripalimab in triple-negative breast cancer, run by Sun Yat-sen University, now recruiting."},{"id":"nct07601178","kind":"trial","name":"QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride","route":"/trials/nct07601178/","status":"recruiting","tldr":"A phase 2 trial of anlotinib and nab-paclitaxel in triple-negative breast cancer, run by Jiangsu Cancer Institute & Hospital, now recruiting."},{"id":"nct06793332","kind":"trial","name":"BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC","route":"/trials/nct06793332/","status":"recruiting","tldr":"A phase 2 trial in triple-negative breast cancer, run by Fudan University, now recruiting."},{"id":"nct06245889","kind":"trial","name":"PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC","route":"/trials/nct06245889/","status":"recruiting","tldr":"A phase 2 trial of paclitaxel / nab-paclitaxel, carboplatin, pembrolizumab, doxorubicin and other drugs in triple-negative breast cancer, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, now recruiting."},{"id":"nct04768426","kind":"trial","name":"Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer","route":"/trials/nct04768426/","status":"recruiting","tldr":"A phase 2 trial of capecitabine in triple-negative breast cancer, run by Stanford University, now recruiting."},{"id":"nct06793553","kind":"trial","name":"Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC","route":"/trials/nct06793553/","status":"recruiting","tldr":"A phase 2 trial in triple-negative breast cancer, run by Japan Breast Cancer Research Group, now recruiting."},{"id":"nct06963905","kind":"trial","name":"Saci Nivo Rela for TNBC","route":"/trials/nct06963905/","status":"recruiting","tldr":"A phase 1/2 trial of nivolumab and sacituzumab govitecan in triple-negative breast cancer, run by Yale University, now recruiting."},{"id":"nct06682195","kind":"trial","name":"Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)","route":"/trials/nct06682195/","status":"recruiting","tldr":"A phase 2 trial of toripalimab in triple-negative breast cancer, run by First Affiliated Hospital of Zhejiang University, now recruiting."},{"id":"nct04683679","kind":"trial","name":"A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negat","route":"/trials/nct04683679/","status":"recruiting","tldr":"A phase 2 trial of pembrolizumab and olaparib in triple-negative breast cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting."},{"id":"nct06353997","kind":"trial","name":"Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients","route":"/trials/nct06353997/","status":"recruiting","tldr":"A phase 2 trial of pembrolizumab and INBRX-106 in triple-negative breast cancer, run by Providence Health & Services, now recruiting."},{"id":"nct04230109","kind":"trial","name":"Sacituzumab Govitecan In TNBC","route":"/trials/nct04230109/","status":"recruiting","tldr":"A phase 2 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer, run by Massachusetts General Hospital, now recruiting."},{"id":"nct06134375","kind":"trial","name":"A Study of Tetrathiomolybdate (TM) Plus Capecitabine","route":"/trials/nct06134375/","status":"recruiting","tldr":"A phase 1/2 trial of capecitabine and pembrolizumab in triple-negative breast cancer, run by Dartmouth-Hitchcock Medical Center, now recruiting."},{"id":"nct06616987","kind":"trial","name":"Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct06616987/","status":"recruiting","tldr":"A phase 2 trial of sacituzumab govitecan and pegfilgrastim in triple-negative breast cancer, run by Yeon Hee Park, now recruiting."},{"id":"nct06385990","kind":"trial","name":"Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy","route":"/trials/nct06385990/","status":"recruiting","tldr":"A phase 2 trial of utidelone in triple-negative breast cancer, run by Hunan Cancer Hospital, now recruiting."},{"id":"nct06367088","kind":"trial","name":"Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer","route":"/trials/nct06367088/","status":"recruiting","tldr":"A phase 2 trial of cadonilimab in triple-negative breast cancer, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, now recruiting."},{"id":"nct06831955","kind":"trial","name":"LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer","route":"/trials/nct06831955/","status":"recruiting","tldr":"A phase 2 trial in triple-negative breast cancer, run by Universitaire Ziekenhuizen KU Leuven, now recruiting."},{"id":"nct07371208","kind":"trial","name":"Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer","route":"/trials/nct07371208/","status":"recruiting","tldr":"A phase 2 trial of sacituzumab tirumotecan in triple-negative breast cancer, run by Shanghai Jiao Tong University School of Medicine, now recruiting."},{"id":"nct06817525","kind":"trial","name":"Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC","route":"/trials/nct06817525/","status":"recruiting","tldr":"A phase 2 trial in triple-negative breast cancer, run by Henan Cancer Hospital, now recruiting."},{"id":"nct07342283","kind":"trial","name":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer","route":"/trials/nct07342283/","status":"recruiting","tldr":"A phase 2 trial in triple-negative breast cancer, run by Affiliated Hospital of Nantong University, now recruiting."},{"id":"nct06878625","kind":"trial","name":"A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer","route":"/trials/nct06878625/","status":"recruiting","tldr":"A phase 2 trial of toripalimab in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting."},{"id":"nct06636981","kind":"trial","name":"All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi","route":"/trials/nct06636981/","status":"recruiting","tldr":"A phase 2 trial of toripalimab in triple-negative breast cancer, run by Fudan University, now recruiting."},{"id":"nct07739485","kind":"trial","name":"Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study","route":"/trials/nct07739485/","status":"recruiting","tldr":"A phase 1/2 trial of epirubicin in triple-negative breast cancer, run by Liu Shu, now recruiting."},{"id":"nct05550415","kind":"trial","name":"The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer","route":"/trials/nct05550415/","status":"recruiting","tldr":"A phase 2 trial in triple-negative breast cancer, run by Universitas Indonesia, now recruiting."},{"id":"nct06078384","kind":"trial","name":"Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC","route":"/trials/nct06078384/","status":"recruiting","tldr":"A phase 2 trial of paclitaxel / nab-paclitaxel in triple-negative breast cancer, run by UNICANCER, now recruiting."},{"id":"nct05866432","kind":"trial","name":"Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases","route":"/trials/nct05866432/","status":"recruiting","tldr":"A phase 2 trial of datopotamab deruxtecan in triple-negative breast cancer, run by Medical University of Vienna, now recruiting."},{"id":"nct06851299","kind":"trial","name":"The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast","route":"/trials/nct06851299/","status":"recruiting","tldr":"A phase 2 trial in triple-negative breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, now recruiting."},{"id":"nct05570253","kind":"trial","name":"A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer","route":"/trials/nct05570253/","status":"recruiting","tldr":"A phase 2 trial of eribulin and evexomostat in triple-negative breast cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting."},{"id":"nct07078604","kind":"trial","name":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","route":"/trials/nct07078604/","status":"recruiting","tldr":"A phase 2 trial of sargramostim in triple-negative breast cancer, run by University of Washington, now recruiting."},{"id":"nct04722978","kind":"trial","name":"Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer","route":"/trials/nct04722978/","status":"recruiting","tldr":"A phase 3 trial of gemcitabine and carboplatin in triple-negative breast cancer, run by Sun Yat-Sen University Cancer Center, now recruiting."},{"id":"nct04437160","kind":"trial","name":"Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy","route":"/trials/nct04437160/","status":"recruiting","tldr":"A phase 2 trial of epirubicin, pirarubicin and cyclophosphamide in triple-negative breast cancer, run by Chinese Academy of Medical Sciences, now recruiting."},{"id":"nct05806060","kind":"trial","name":"Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct05806060/","status":"recruiting","tldr":"A phase 3 trial in triple-negative breast cancer, run by Fudan University, now recruiting."},{"id":"nct05660083","kind":"trial","name":"Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)","route":"/trials/nct05660083/","status":"recruiting","tldr":"A phase 2 trial in triple-negative breast cancer, run by The Methodist Hospital Research Institute, now recruiting."},{"id":"nct06358573","kind":"trial","name":"Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK","route":"/trials/nct06358573/","status":"recruiting","tldr":"A phase 2 trial of INT230-6 in triple-negative breast cancer, run by Swiss Cancer Institute, now recruiting."},{"id":"nct07276880","kind":"trial","name":"Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer","route":"/trials/nct07276880/","status":"recruiting","tldr":"A phase 2 trial in triple-negative breast cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting."},{"id":"nct06081244","kind":"trial","name":"NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)","route":"/trials/nct06081244/","status":"recruiting","tldr":"A phase 3 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer, run by Women's Cancer Study Group GmbH, now recruiting."},{"id":"nct07394387","kind":"trial","name":"Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.","route":"/trials/nct07394387/","status":"recruiting","tldr":"A phase 2 trial of sintilimab, nab-paclitaxel and carboplatin in triple-negative breast cancer, run by The First Affiliated Hospital with Nanjing Medical University, now recruiting."},{"id":"nct07045311","kind":"trial","name":"JS207 Combination Therapy in Triple-negative Breast Cancer","route":"/trials/nct07045311/","status":"recruiting","tldr":"A phase 2 trial in triple-negative breast cancer, run by Shanghai Junshi Bioscience Co., Ltd., now recruiting."},{"id":"nct07768436","kind":"trial","name":"A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer","route":"/trials/nct07768436/","status":"recruiting","tldr":"A phase 2 trial of paclitaxel / nab-paclitaxel in triple-negative breast cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting."},{"id":"nct05475678","kind":"trial","name":"Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer","route":"/trials/nct05475678/","status":"recruiting","tldr":"A phase 2 trial in triple-negative breast cancer, run by Zhenzhen Liu, now recruiting."},{"id":"nct06976944","kind":"trial","name":"Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer","route":"/trials/nct06976944/","status":"recruiting","tldr":"A phase 2 trial of pembrolizumab, paclitaxel / nab-paclitaxel and bevacizumab in triple-negative breast cancer, run by Yukinori Ozaki, now recruiting."},{"id":"nct04481763","kind":"trial","name":"A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast","route":"/trials/nct04481763/","status":"recruiting","tldr":"A phase 1/2 trial of camrelizumab in triple-negative breast cancer, run by Jiangxi Provincial Cancer Hospital, now recruiting."},{"id":"nct05999149","kind":"trial","name":"A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BC","route":"/trials/nct05999149/","status":"recruiting","tldr":"A phase 3 trial of camrelizumab in triple-negative breast cancer, run by Fudan University, now recruiting."},{"id":"nct07743190","kind":"trial","name":"A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) P","route":"/trials/nct07743190/","status":"recruiting","tldr":"A phase 2 trial of carboplatin and pembrolizumab in triple-negative breast cancer, run by Medical University of South Carolina, now recruiting."},{"id":"nct05035745","kind":"trial","name":"Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)","route":"/trials/nct05035745/","status":"recruiting","tldr":"A phase 1/2 trial of talazoparib and selinexor in triple-negative breast cancer, run by National University Hospital, Singapore, now recruiting."},{"id":"nct04159818","kind":"trial","name":"Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients","route":"/trials/nct04159818/","status":"recruiting","tldr":"A phase 2 trial of nivolumab and cisplatin in triple-negative breast cancer, run by The Netherlands Cancer Institute, now recruiting."},{"id":"nct05192798","kind":"trial","name":"Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC","route":"/trials/nct05192798/","status":"recruiting","tldr":"A phase 2 trial of nab-paclitaxel, rivoceranib (apatinib) and bevacizumab in triple-negative breast cancer, run by The First Affiliated Hospital of Bengbu Medical University, now recruiting."},{"id":"nct06313463","kind":"trial","name":"Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy","route":"/trials/nct06313463/","status":"recruiting","tldr":"A phase 3 trial of capecitabine in triple-negative breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, now recruiting."},{"id":"nct06538896","kind":"trial","name":"Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Mu","route":"/trials/nct06538896/","status":"recruiting","tldr":"A phase 2 trial of tislelizumab and nab-paclitaxel in triple-negative breast cancer, run by Zhejiang Cancer Hospital, now recruiting."},{"id":"nct05749588","kind":"trial","name":"FUSCC Refractory TNBC Platform Study (FUTURE2.0)","route":"/trials/nct05749588/","status":"recruiting","tldr":"A phase 2 trial of camrelizumab, everolimus, TQB2102 and TQB2868 in triple-negative breast cancer, run by Fudan University, now recruiting."},{"id":"nct07321015","kind":"trial","name":"A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance","route":"/trials/nct07321015/","status":"recruiting","tldr":"A phase 2 trial in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting."},{"id":"nct06786026","kind":"trial","name":"QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC","route":"/trials/nct06786026/","status":"recruiting","tldr":"A phase 2 trial of bevacizumab, iparomlimab and tuvonralimab and nab-paclitaxel in triple-negative breast cancer, run by Fudan University, now recruiting."},{"id":"nct06238921","kind":"trial","name":"Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases","route":"/trials/nct06238921/","status":"recruiting","tldr":"A phase 1/2 trial of zimberelimab and sacituzumab govitecan in triple-negative breast cancer, run by H. Lee Moffitt Cancer Center and Research Institute, now recruiting."},{"id":"nct04677816","kind":"trial","name":"Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients","route":"/trials/nct04677816/","status":"recruiting","tldr":"A phase 2 trial in triple-negative breast cancer, run by Wake Forest University Health Sciences, now recruiting."},{"id":"nct07069595","kind":"trial","name":"PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease","route":"/trials/nct07069595/","status":"recruiting","tldr":"A phase 2 trial of datopotamab deruxtecan in triple-negative breast cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting."},{"id":"nct06532812","kind":"trial","name":"TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer","route":"/trials/nct06532812/","status":"recruiting","tldr":"A phase 1/2 trial of fludarabine, aldesleukin (high-dose il-2) and pembrolizumab in triple-negative breast cancer, run by Essen Biotech, now recruiting."},{"id":"nct06387628","kind":"trial","name":"LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer","route":"/trials/nct06387628/","status":"recruiting","tldr":"A phase 2 trial of LM-108, toripalimab, eribulin and nab-paclitaxel in triple-negative breast cancer, run by Fudan University, now recruiting."},{"id":"nct05528133","kind":"trial","name":"Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer","route":"/trials/nct05528133/","status":"recruiting","tldr":"A phase 2 trial in triple-negative breast cancer, run by H. Lee Moffitt Cancer Center and Research Institute, now recruiting."},{"id":"nct07401537","kind":"trial","name":"Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer","route":"/trials/nct07401537/","status":"recruiting","tldr":"A phase 2 trial in triple-negative breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, now recruiting."},{"id":"nct05296564","kind":"trial","name":"Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers","route":"/trials/nct05296564/","status":"recruiting","tldr":"A phase 1/2 trial of cyclophosphamide and aldesleukin (high-dose il-2) in triple-negative breast cancer, run by Hadassah Medical Organization, now recruiting."},{"id":"nct06845319","kind":"trial","name":"NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients","route":"/trials/nct06845319/","status":"recruiting","tldr":"A phase 2 trial of carboplatin, paclitaxel / nab-paclitaxel and pembrolizumab in triple-negative breast cancer, run by Medical University of South Carolina, now recruiting."},{"id":"nct03606967","kind":"trial","name":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct03606967/","status":"recruiting","tldr":"A phase 2 trial of carboplatin, durvalumab, gemcitabine, nab-paclitaxel and other drugs in triple-negative breast cancer, run by National Cancer Institute (NCI), now recruiting."},{"id":"nct04138719","kind":"trial","name":"Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer","route":"/trials/nct04138719/","status":"recruiting","tldr":"A phase 2 trial of nab-paclitaxel, carboplatin and epirubicin in triple-negative breast cancer, run by Hebei Medical University Fourth Hospital, now recruiting."},{"id":"nct06678048","kind":"trial","name":"Arsenous Acid for Refractory Triple-Negative Breast Cancer","route":"/trials/nct06678048/","status":"recruiting","tldr":"A phase 2 trial in triple-negative breast cancer, run by Sun Yat-sen University, now recruiting."},{"id":"nct05491226","kind":"trial","name":"Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation","route":"/trials/nct05491226/","status":"recruiting","tldr":"A phase 2 trial of pembrolizumab in triple-negative breast cancer, run by Stephen Shiao, now recruiting."},{"id":"nct05582538","kind":"trial","name":"Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel","route":"/trials/nct05582538/","status":"recruiting","tldr":"A phase 2 trial of ceralasertib, durvalumab and nab-paclitaxel in triple-negative breast cancer, run by IFOM ETS - The AIRC Institute of Molecular Oncology, now recruiting."},{"id":"nct06840821","kind":"trial","name":"Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptor","route":"/trials/nct06840821/","status":"recruiting","tldr":"A phase 1/2 trial in triple-negative breast cancer, run by Mainline Biosciences (Shanghai) Co., Ltd, now recruiting."},{"id":"nct07623577","kind":"trial","name":"Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases","route":"/trials/nct07623577/","status":"recruiting","tldr":"A phase 2 trial of sacituzumab tirumotecan and bevacizumab in triple-negative breast cancer, run by Fudan University, now recruiting."},{"id":"nct06690840","kind":"trial","name":"Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients","route":"/trials/nct06690840/","status":"recruiting","tldr":"A phase 2 trial of atezolizumab, cyclophosphamide and vinorelbine in triple-negative breast cancer, run by European Institute of Oncology, now recruiting."},{"id":"nct06125080","kind":"trial","name":"The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospec","route":"/trials/nct06125080/","status":"recruiting","tldr":"A phase 2 trial of utidelone and bevacizumab in triple-negative breast cancer, run by Huihua Xiong, now recruiting."},{"id":"nct05485766","kind":"trial","name":"Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer","route":"/trials/nct05485766/","status":"recruiting","tldr":"A phase 2 trial of pembrolizumab, paclitaxel / nab-paclitaxel, carboplatin and olaparib in triple-negative breast cancer, run by Okayama University, now recruiting."},{"id":"nct07340541","kind":"trial","name":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","route":"/trials/nct07340541/","status":"recruiting","tldr":"A phase 2 trial of abemaciclib, everolimus and capecitabine in triple-negative breast cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting."},{"id":"nct06365788","kind":"trial","name":"Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer","route":"/trials/nct06365788/","status":"recruiting","tldr":"A phase 2 trial of abemaciclib and bicalutamide in triple-negative breast cancer, run by Universitaire Ziekenhuizen KU Leuven, now recruiting."},{"id":"nct07017673","kind":"trial","name":"Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer","route":"/trials/nct07017673/","status":"recruiting","tldr":"A phase 2 trial of ivonescimab, carboplatin and docetaxel in triple-negative breast cancer, run by Cedars-Sinai Medical Center, now recruiting."},{"id":"nct07638852","kind":"trial","name":"Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.","route":"/trials/nct07638852/","status":"recruiting","tldr":"A phase 2 trial of bevacizumab, cisplatin and carboplatin in triple-negative breast cancer, run by Fudan University, now recruiting."},{"id":"nct04333706","kind":"trial","name":"A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of S","route":"/trials/nct04333706/","status":"recruiting","tldr":"A phase 1/2 trial of capecitabine in triple-negative breast cancer, run by University of Southern California, now recruiting."},{"id":"nct06165900","kind":"trial","name":"Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC","route":"/trials/nct06165900/","status":"recruiting","tldr":"A phase 2 trial of adebrelimab and carboplatin in triple-negative breast cancer, run by Shengjing Hospital, now recruiting."},{"id":"nct06508216","kind":"trial","name":"A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negat","route":"/trials/nct06508216/","status":"recruiting","tldr":"A phase 1/2 trial of datopotamab deruxtecan and durvalumab in triple-negative breast cancer, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting."},{"id":"nct06225284","kind":"trial","name":"Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients","route":"/trials/nct06225284/","status":"recruiting","tldr":"A phase 2 trial in triple-negative breast cancer, run by National Taiwan University Hospital, now recruiting."},{"id":"nct06889688","kind":"trial","name":"Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer","route":"/trials/nct06889688/","status":"recruiting","tldr":"A phase 3 trial of camrelizumab, rivoceranib (apatinib) and eribulin in triple-negative breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, now recruiting."},{"id":"nct05019690","kind":"trial","name":"Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer","route":"/trials/nct05019690/","status":"recruiting","tldr":"A phase 1/2 trial of rivoceranib (apatinib) and nab-paclitaxel in triple-negative breast cancer, run by Fujian Cancer Hospital, now recruiting."},{"id":"nct04137653","kind":"trial","name":"Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT","route":"/trials/nct04137653/","status":"recruiting","tldr":"A phase 3 trial of nab-paclitaxel, carboplatin and paclitaxel / nab-paclitaxel in triple-negative breast cancer, run by Shengjing Hospital, now recruiting."},{"id":"nct06380816","kind":"trial","name":"A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer","route":"/trials/nct06380816/","status":"recruiting","tldr":"A phase 1/2 trial in triple-negative breast cancer, run by Cancer Research UK, now recruiting."},{"id":"nct05973864","kind":"trial","name":"Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery","route":"/trials/nct05973864/","status":"recruiting","tldr":"A phase 2 trial of pembrolizumab and capecitabine in triple-negative breast cancer, run by UNICANCER, now recruiting."},{"id":"nct05862064","kind":"trial","name":"A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chem","route":"/trials/nct05862064/","status":"recruiting","tldr":"A phase 3 trial of epirubicin, cyclophosphamide and paclitaxel / nab-paclitaxel in triple-negative breast cancer, run by Fudan University, now recruiting."},{"id":"nct06492759","kind":"trial","name":"High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer","route":"/trials/nct06492759/","status":"recruiting","tldr":"A phase 2 trial of pembrolizumab, nab-paclitaxel, paclitaxel / nab-paclitaxel, carboplatin and other drugs in triple-negative breast cancer, run by Emory University, now recruiting."},{"id":"nct05846789","kind":"trial","name":"Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers","route":"/trials/nct05846789/","status":"recruiting","tldr":"A phase 2 trial of tocilizumab in triple-negative breast cancer, run by Kathy Miller, now recruiting."},{"id":"nct06889610","kind":"trial","name":"A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.","route":"/trials/nct06889610/","status":"recruiting","tldr":"A phase 2 trial in triple-negative breast cancer, run by Fudan University, now recruiting."},{"id":"nct06318897","kind":"trial","name":"Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T","route":"/trials/nct06318897/","status":"recruiting","tldr":"A phase 2 trial of carboplatin, paclitaxel / nab-paclitaxel, pembrolizumab, doxorubicin and other drugs in triple-negative breast cancer, run by M.D. Anderson Cancer Center, now recruiting."},{"id":"nct06534762","kind":"trial","name":"Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study","route":"/trials/nct06534762/","status":"recruiting","tldr":"A phase 2 trial in triple-negative breast cancer, run by Zhejiang Provincial People's Hospital, now recruiting."},{"id":"nct05909332","kind":"trial","name":"Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)","route":"/trials/nct05909332/","status":"recruiting","tldr":"A phase 3 trial in triple-negative breast cancer, run by Fudan University, now recruiting."},{"id":"nct06771609","kind":"trial","name":"Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy fo","route":"/trials/nct06771609/","status":"recruiting","tldr":"A phase 2 trial of adebrelimab in triple-negative breast cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting."},{"id":"nct06434064","kind":"trial","name":"Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer","route":"/trials/nct06434064/","status":"recruiting","tldr":"A phase 2 trial of doxorubicin and tamoxifen in triple-negative breast cancer, run by Roswell Park Cancer Institute, now recruiting."},{"id":"nct06606730","kind":"trial","name":"Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer","route":"/trials/nct06606730/","status":"recruiting","tldr":"A phase 3 trial of pembrolizumab in triple-negative breast cancer, run by UNICANCER, now recruiting."},{"id":"nct05770531","kind":"trial","name":"Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy","route":"/trials/nct05770531/","status":"recruiting","tldr":"A phase 2 trial of sacituzumab govitecan in triple-negative breast cancer, run by Vanderbilt-Ingram Cancer Center, now recruiting."},{"id":"nct06291064","kind":"trial","name":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer","route":"/trials/nct06291064/","status":"recruiting","tldr":"A phase 2 trial of cyclophosphamide, epirubicin, docetaxel, carboplatin and other drugs in triple-negative breast cancer, run by University of Chicago, now recruiting."},{"id":"nct07351487","kind":"trial","name":"Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)","route":"/trials/nct07351487/","status":"recruiting","tldr":"A phase 2 trial of sintilimab and bevacizumab in triple-negative breast cancer, run by First Affiliated Hospital of Zhejiang University, now recruiting."},{"id":"nct06401005","kind":"trial","name":"SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)","route":"/trials/nct06401005/","status":"recruiting","tldr":"A phase 2 trial of cadonilimab in triple-negative breast cancer, run by Hubei Cancer Hospital, now recruiting."},{"id":"nct07016399","kind":"trial","name":"Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC","route":"/trials/nct07016399/","status":"recruiting","tldr":"A phase 2 trial of carboplatin, cyclophosphamide, darolutamide, doxorubicin and other drugs in triple-negative breast cancer, run by Vandana Abramson, now recruiting."},{"id":"nct07457359","kind":"trial","name":"Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer","route":"/trials/nct07457359/","status":"recruiting","tldr":"A phase 2 trial of toripalimab in triple-negative breast cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting."},{"id":"nct06735131","kind":"trial","name":"The Optimal Radioimmunotherapy Combinations for Advanced TNBC","route":"/trials/nct06735131/","status":"recruiting","tldr":"A phase 2 trial of toripalimab in triple-negative breast cancer, run by Sun Yat-sen University, now recruiting."},{"id":"nct06992336","kind":"trial","name":"Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy","route":"/trials/nct06992336/","status":"recruiting","tldr":"A phase 2 trial of anlotinib, benmelstobart and capecitabine in triple-negative breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, now recruiting."},{"id":"nct07011654","kind":"trial","name":"Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)","route":"/trials/nct07011654/","status":"recruiting","tldr":"A phase 1/2 trial of sacituzumab govitecan and naxitamab in triple-negative breast cancer, run by M.D. Anderson Cancer Center, now recruiting."},{"id":"nct06533384","kind":"trial","name":"PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC","route":"/trials/nct06533384/","status":"recruiting","tldr":"A phase 3 trial of capecitabine in triple-negative breast cancer, run by Guangdong Provincial People's Hospital, now recruiting."},{"id":"nct05760378","kind":"trial","name":"Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.","route":"/trials/nct05760378/","status":"recruiting","tldr":"A phase 3 trial of camrelizumab, capecitabine, eribulin and carboplatin in triple-negative breast cancer, run by Fudan University, now recruiting."},{"id":"nct07074106","kind":"trial","name":"TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC","route":"/trials/nct07074106/","status":"recruiting","tldr":"A phase 2 trial of carboplatin in triple-negative breast cancer, run by D'Or Institute for Research and Education, now recruiting."},{"id":"nct04434040","kind":"trial","name":"Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)","route":"/trials/nct04434040/","status":"recruiting","tldr":"A phase 2 trial of atezolizumab and sacituzumab govitecan in triple-negative breast cancer, run by Dana-Farber Cancer Institute, now recruiting."},{"id":"nct04501523","kind":"trial","name":"A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC","route":"/trials/nct04501523/","status":"recruiting","tldr":"A phase 2 trial of tislelizumab and capecitabine in triple-negative breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, now recruiting."},{"id":"nct03808337","kind":"trial","name":"Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Origina","route":"/trials/nct03808337/","status":"recruiting","tldr":"A phase 2 trial in triple-negative breast cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting."},{"id":"nct07283692","kind":"trial","name":"Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)","route":"/trials/nct07283692/","status":"recruiting","tldr":"A phase 2 trial of serplulimab, paclitaxel / nab-paclitaxel and carboplatin in triple-negative breast cancer, run by RenJi Hospital, now recruiting."},{"id":"nct06342037","kind":"trial","name":"NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial","route":"/trials/nct06342037/","status":"recruiting","tldr":"A phase 2 trial of tiragolumab, atezolizumab and ipilimumab in triple-negative breast cancer, run by The Netherlands Cancer Institute, now recruiting."},{"id":"nct07188246","kind":"trial","name":"Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer","route":"/trials/nct07188246/","status":"recruiting","tldr":"A phase 2 trial of pembrolizumab in triple-negative breast cancer, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, now recruiting."},{"id":"nct06802757","kind":"trial","name":"Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer","route":"/trials/nct06802757/","status":"recruiting","tldr":"A phase 2 trial of nab-paclitaxel, carboplatin and cyclophosphamide in triple-negative breast cancer, run by Shandong Cancer Hospital and Institute, now recruiting."},{"id":"nct05451784","kind":"trial","name":"Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS","route":"/trials/nct05451784/","status":"recruiting","tldr":"A phase 1/2 trial in triple-negative breast cancer, run by Fundacio Clinic Barcelona, now recruiting."},{"id":"nct05491083","kind":"trial","name":"Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer","route":"/trials/nct05491083/","status":"recruiting","tldr":"A phase 1/2 trial in triple-negative breast cancer, run by National University Hospital, Singapore, now recruiting."},{"id":"nct07104266","kind":"trial","name":"Triple Negative Breast Cancer and Celecoxib. Pilot Study","route":"/trials/nct07104266/","status":"recruiting","tldr":"A phase 2 trial of celecoxib in triple-negative breast cancer, run by Université de Sherbrooke, now recruiting."},{"id":"nct05269381","kind":"trial","name":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","route":"/trials/nct05269381/","status":"recruiting","tldr":"A phase 1/2 trial of cyclophosphamide, pembrolizumab and sargramostim in triple-negative breast cancer, run by Mayo Clinic, now recruiting."},{"id":"nct04159142","kind":"trial","name":"Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer","route":"/trials/nct04159142/","status":"recruiting","tldr":"A phase 2 trial of nab-paclitaxel, carboplatin and capecitabine in triple-negative breast cancer, run by Hebei Medical University Fourth Hospital, now recruiting."},{"id":"nct04947189","kind":"trial","name":"Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer","route":"/trials/nct04947189/","status":"recruiting","tldr":"A phase 1/2 trial of dexamethasone and docetaxel in triple-negative breast cancer, run by St Vincent's Hospital, Sydney, now recruiting."},{"id":"nct06635980","kind":"trial","name":"Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer","route":"/trials/nct06635980/","status":"recruiting","tldr":"A phase 2 trial in triple-negative breast cancer, run by Mayo Clinic, now recruiting."},{"id":"nct04771871","kind":"trial","name":"MicroRNA Profiles in Triple Negative Breast Cancer","route":"/trials/nct04771871/","status":"recruiting","tldr":"A phase 2 trial of epirubicin, cyclophosphamide, paclitaxel / nab-paclitaxel and carboplatin in triple-negative breast cancer, run by University College Hospital, Ibadan, now recruiting."}]}